Gledhill Tamsin, Bodger Keith
Digestive Diseases Centre, Aintree University Hospital Trust, Liverpool, UK.
Biologics. 2013;7:123-30. doi: 10.2147/BTT.S30416. Epub 2013 May 23.
Ulcerative colitis (UC) is the most common form of chronic inflammatory bowel disease and lacks a curative pharmacological treatment. Traditional therapies, which include 5-aminosalicylates, corticosteroids and immunosuppressants, aim to induce and maintain remission. Biological therapy with anti-tumor necrosis factor-alpha agents has added to the range of available treatments. Vedolizumab belongs to a new class of agents (integrin antagonists) that inhibit leukocyte adhesion and aim to selectively inhibit the inflammatory pathway. This article reviews the emerging data on the use of vedolizumab for UC. Evidence to date supports its efficacy in inducing remission in UC, with no major safety concerns identified.
溃疡性结肠炎（UC）是慢性炎症性肠病最常见的形式，目前缺乏治愈性的药物治疗方法。传统疗法包括5-氨基水杨酸类、皮质类固醇和免疫抑制剂，旨在诱导和维持病情缓解。使用抗肿瘤坏死因子-α药物的生物疗法增加了可用治疗方法的范围。维多珠单抗属于一类新型药物（整合素拮抗剂），可抑制白细胞黏附，旨在选择性抑制炎症途径。本文综述了有关维多珠单抗用于治疗UC的最新数据。迄今为止的证据支持其在诱导UC病情缓解方面的疗效，且未发现重大安全问题。
